On 21 October 2022 the extraordinary general shareholders' meeting of Epigenomics AG has resolved a reduction of the share capital at a ratio of 4:1. The capital reduction shall be effected for the purpose of offsetting losses and the allocation to the capital reserve of the company. The extraordinary general shareholders' meeting was held in a new virtual setting in accordance with the new German legal provisions that came into force in July 2022.
Hengeler Mueller advised Epigenomics on the virtual extraordinary general shareholders' meeting. The team included partner Kai-Steffen Scholz as well as associate Philipp Pauschinger (both Corporate, Berlin).